NEW YORK – The European Medicines Agency has given the green light to an investigator-initiated trial of Lantern Pharma's lead drug candidate LP-184 (zirdafulven) for advanced, recurrent bladder ...

The company closed an upsized IPO and concurrent private placement to Sanofi, proceeds of which will fund its pipeline of CRISPR-based medicines.

The firm's oncology unit reported 16 percent growth in Q2, with nearly all oncology medicines reporting revenue growth in the ...

Estrella Immunopharma's first trial of its CD19-directed autologous T-cell therapy for non-Hodgkin's lymphoma is progressing smoothly, the company said late last week, and it has moved on to the dose ...

NEW YORK – Oak Hill Bio on Monday said it plans to go public through a merger with Research Alliance Corporation III (RACC), a special purpose acquisition company (SPAC), and raise funds to develop ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday recommended approval for AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug ...

It is also preclinically testing three RNA vaccines — one for cytomegalovirus-driven colorectal cancer, glioblastoma, and triple-negative breast cancer, a second for HPV-positive head and neck cancers ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended market authorization for Gilead's Trodelvy with Merck's checkpoint inhibitor Keytruda ...

The approval was based on the Phase III SERENA-6 trial that used ctDNA testing to detect ESR1 resistance mutations and inform treatment switching.

A Children's Hospital of Philadelphia team said their case study highlighted the need for increased safety monitoring.

A deal with Regeneron announced in April could push the firm's revenue and income totals past $1 billion by year end.

The firm reported that two Phase III trials of Redemplo met their primary endpoints of lowering patients' triglyceride levels.